|
May 15
|
NanoViricides Has Filed its Quarterly Report
|
|
May 14
|
A Novel Broad-Spectrum Antiviral with Activity Against RSV
|
|
May 10
|
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
|
|
May 8
|
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
|
|
May 6
|
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
|
|
May 2
|
3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire
|
|
Apr 30
|
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
|
|
Jan 4
|
NanoViricides to Present at the Biotech Showcase in San Fransisco
|
|
Nov 29
|
NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387
|
|
Nov 28
|
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
|
|
Aug 31
|
NanoViricides progressing well with new Covid study
|
|
Jun 29
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
|
|
Apr 25
|
NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
|